ENZYCHEM LIFESCIENCES CORPORATION: debt-to-equity, ROE and more
KOSDAQ, Legal name ENZYCHEM LIFESCIENCES CORPORATION
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 7.1%
- Equity ratio
- 93.4%
- ROE
- -13.0%
- Op. margin
- -21.2%
- Rev. growth
- -12.4%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 78.2% | 56.1% | -37.3% | -90.3% | n/a |
| FY2022 consolidated | 22.7% | 81.5% | -12.4% | -55.0% | 15.9% |
| FY2023 consolidated | 8.7% | 92.0% | -4.8% | -18.9% | 185.5% |
| FY2024 consolidated | 12.5% | 88.9% | -13.7% | -17.1% | 1.8% |
| FY2025 consolidated | 7.1% | 93.4% | -13.0% | -21.2% | -12.4% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩23.0B | ₩26.6B | ₩76.0B | ₩77.4B | ₩67.8B |
| Operating profit | -₩20.8B | -₩14.7B | -₩14.4B | -₩13.2B | -₩14.3B |
| Pre-tax income | -₩29.5B | -₩25.6B | -₩9.9B | -₩22.1B | -₩18.2B |
| Net income | -₩27.9B | -₩25.1B | -₩9.4B | -₩22.1B | -₩18.1B |
| Total assets | ₩133.1B | ₩247.6B | ₩211.5B | ₩181.7B | ₩148.6B |
| Total liabilities | ₩58.4B | ₩45.8B | ₩16.9B | ₩20.3B | ₩9.8B |
| Total equity | ₩74.7B | ₩201.7B | ₩194.6B | ₩161.5B | ₩138.8B |
| Paid-in capital | ₩4.4B | ₩42.4B | ₩42.5B | ₩42.5B | ₩42.5B |
| Debt/equity (source value) | 78.2% | 22.7% | 8.7% | 12.5% | 7.1% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1999-07-20
- Listed
- 18/02/21
- Employees
- 116
- Auditor
- 이촌회계법인
- Audit opinion
- 의견거절
- Corporate reg. no.
- 1601110084890
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 엔지켐생명과학Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.